Modality
Nanobody
MOA
JAK1i
Target
PRMT5
Pathway
RNA Splicing
DMD
Development Pipeline
Preclinical
~Oct 2022
→ ~Jan 2024
Phase 1
Apr 2024
→ Oct 2028
Phase 1Current
NCT07996744
97 pts·DMD
2024-04→2028-10·Recruiting
97 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-10-192.6y awayPh2 Data· DMD
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1/2
Recruit…
Catalysts
Ph2 Data
2028-10-19 · 2.6y away
DMD
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07996744 | Phase 1/2 | DMD | Recruiting | 97 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| Darafutibatinib | BioNTech | Preclinical | PRMT5 |